Country Trust Bank held its stake in shares of Abbott Laboratories (NYSE:ABT) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,502 shares of the healthcare product maker’s stock at the end of the second quarter. Country Trust Bank’s holdings in Abbott Laboratories were worth $267,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. V Wealth Management LLC bought a new position in shares of Abbott Laboratories in the second quarter valued at $127,000. Atwood & Palmer Inc. grew its stake in shares of Abbott Laboratories by 157.5% in the first quarter. Atwood & Palmer Inc. now owns 3,270 shares of the healthcare product maker’s stock valued at $145,000 after buying an additional 2,000 shares in the last quarter. Farmers National Bank grew its stake in shares of Abbott Laboratories by 1.5% in the first quarter. Farmers National Bank now owns 3,568 shares of the healthcare product maker’s stock valued at $158,000 after buying an additional 52 shares in the last quarter. Advantage Investment Management LLC grew its stake in shares of Abbott Laboratories by 17.3% in the first quarter. Advantage Investment Management LLC now owns 3,674 shares of the healthcare product maker’s stock valued at $163,000 after buying an additional 543 shares in the last quarter. Finally, Delta Asset Management LLC TN grew its stake in shares of Abbott Laboratories by 1.3% in the first quarter. Delta Asset Management LLC TN now owns 3,996 shares of the healthcare product maker’s stock valued at $178,000 after buying an additional 51 shares in the last quarter. 71.50% of the stock is owned by institutional investors.

Shares of Abbott Laboratories (NYSE:ABT) opened at 55.00 on Friday. The firm has a market cap of $95.56 billion, a P/E ratio of 77.03 and a beta of 1.06. Abbott Laboratories has a 12-month low of $37.38 and a 12-month high of $55.11. The stock’s 50 day moving average price is $51.71 and its 200-day moving average price is $47.76.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings results on Thursday, July 20th. The healthcare product maker reported $0.62 earnings per share for the quarter, topping the consensus estimate of $0.60 by $0.02. The company had revenue of $6.64 billion during the quarter, compared to the consensus estimate of $6.63 billion. Abbott Laboratories had a return on equity of 14.43% and a net margin of 4.96%. The firm’s quarterly revenue was up 24.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.55 EPS. On average, analysts predict that Abbott Laboratories will post $2.49 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Wednesday, November 15th. Stockholders of record on Friday, October 13th will be paid a dividend of $0.265 per share. The ex-dividend date is Thursday, October 12th. This represents a $1.06 annualized dividend and a dividend yield of 1.93%. Abbott Laboratories’s payout ratio is 149.30%.

ILLEGAL ACTIVITY NOTICE: “Country Trust Bank Maintains Stake in Abbott Laboratories (ABT)” was first published by Watch List News and is owned by of Watch List News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The original version of this news story can be viewed at https://www.watchlistnews.com/country-trust-bank-maintains-stake-in-abbott-laboratories-abt/1616632.html.

In other news, insider Daniel Gesua Sive Salvadori sold 62,460 shares of the stock in a transaction on Tuesday, September 26th. The stock was sold at an average price of $52.95, for a total transaction of $3,307,257.00. Following the completion of the transaction, the insider now owns 113,426 shares in the company, valued at approximately $6,005,906.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Sharon J. Bracken sold 2,000 shares of the stock in a transaction on Tuesday, August 1st. The stock was sold at an average price of $49.16, for a total value of $98,320.00. Following the transaction, the insider now owns 28,806 shares of the company’s stock, valued at approximately $1,416,102.96. The disclosure for this sale can be found here. Insiders have sold a total of 333,310 shares of company stock valued at $16,857,255 in the last quarter. 0.76% of the stock is owned by corporate insiders.

Several equities analysts recently weighed in on the stock. J P Morgan Chase & Co assumed coverage on shares of Abbott Laboratories in a research note on Friday. They issued a “neutral” rating and a $60.00 target price for the company. Bank of America Corporation reissued a “buy” rating and issued a $60.00 target price (up from $56.00) on shares of Abbott Laboratories in a research note on Wednesday. Royal Bank Of Canada reissued a “buy” rating and issued a $55.00 target price on shares of Abbott Laboratories in a research note on Tuesday, October 3rd. BMO Capital Markets reissued a “hold” rating and issued a $53.00 target price on shares of Abbott Laboratories in a research note on Monday, October 2nd. Finally, Barclays PLC raised their target price on shares of Abbott Laboratories from $57.00 to $60.00 and gave the company an “overweight” rating in a research note on Thursday, September 28th. Eight equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $54.75.

Abbott Laboratories Profile

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with Analyst Ratings Network's FREE daily email newsletter.